Literature DB >> 32662193

The Feasibility and Outcomes of Genetic Testing for Autism and Neurodevelopmental Disorders on an Inpatient Child and Adolescent Psychiatry Service.

Aaron D Besterman1,2,3,4, Joshua Sadik4, Michael J Enenbach1,2,4, Fabiola Quintero-Rivera4,5, Mark DeAntonio1,2,4, Julian A Martinez-Agosto2,3,4,6.   

Abstract

Diagnostic genetic testing is recommended for children with autism spectrum disorder and other neurodevelopmental disorders. One approach to improve access to genetic testing is to offer it on the inpatient child and adolescent psychiatry (CAP) service. We provided medical genetics education to CAP fellows and retrospectively compared the genetic testing rates and diagnostic yield pre- and post-education. We compared demographics to similar patients who received testing on other clinical services and assessed rates of outpatient genetics follow-up post-discharge. The genetic testing rate on the inpatient CAP service was 1.6% before the educational intervention and 10.7% afterward. Genetic risk factors were identified in 4.3% of inpatients. However, 34.8% had variants of unknown significance. 39.1% of patients who received genetic testing while inpatients were underrepresented minorities, compared to 7.7% of inpatients who received genetic testing from other clinical services. 43.5% of patients were lost to outpatient genetics follow-up. We have demonstrated that it is feasible to provide medical genetics education to CAP fellows on an inpatient service, which may improve genetic testing rates. This preliminary evidence also suggests that genetic testing for inpatients may identify variants of unknown significance instead of well-known neurodevelopmental disorder risk variants. Genetic testing on an inpatient CAP service may also improve access to genetic services for underrepresented minorities, but assuring outpatient follow-up can be challenging. LAY
SUMMARY: Genetic testing is recommended for children with autism and related developmental conditions. We provided genetic testing to a group of these children who were in a psychiatric hospital by teaching their doctors how it can be helpful. We identified a genetic risk factor in a small percentage of children and a possible genetic risk factor in a large percentage of children. However, many children did not end up receiving their genetic test results once they left the hospital. These results tell us that the psychiatric hospital may be a good place for children with autism and behavioral problems to get genetic testing, but that it is really important that doctors assure follow-up is feasible for all patients to receive their genetic test results once they leave the hospital. Autism Res 2020, 13: 1450-1464.
© 2020 International Society for Autism Research, Wiley Periodicals, Inc. © 2020 International Society for Autism Research, Wiley Periodicals, LLC.

Entities:  

Keywords:  autism spectrum disorder; child psychiatry; genetic testing; inpatients; medical genetics; neurodevelopmental disorders

Mesh:

Year:  2020        PMID: 32662193     DOI: 10.1002/aur.2338

Source DB:  PubMed          Journal:  Autism Res        ISSN: 1939-3806            Impact factor:   4.633


  3 in total

1.  Autism Spectrum Disorder and Genetic Testing: Parents' Attitudes-Data from Turkish Sample.

Authors:  Aynur Bütün Ayhan; Utku Beyazıt; Şenay Topuz; Çağla Zeynep Tunay; Maryam Nazhad Abbas; Serkan Yılmaz
Journal:  J Autism Dev Disord       Date:  2020-11-21

2.  A Collaborative Psychiatric-Genetics Inpatient Care Delivery Model Improves Access to Clinical Genetic Evaluation, Testing, and Diagnosis for Patients With Neurodevelopmental Disorders.

Authors:  Amelle Shillington; Martine Lamy; Kelli C Dominick; Michael Sorter; Craig A Erickson; Robert Hopkin
Journal:  Front Genet       Date:  2022-06-13       Impact factor: 4.772

3.  Next-generation gene panel testing in adolescents and adults in a medical neuropsychiatric genetics clinic.

Authors:  Y Trakadis; A Accogli; B Qi; D Bloom; R Joober; E Levy; K Tabbane
Journal:  Neurogenetics       Date:  2021-08-07       Impact factor: 2.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.